The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- PMID: 21514249
- PMCID: PMC3312027
- DOI: 10.1016/j.jalz.2011.03.008
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Abstract
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.
Copyright © 2011 The Alzheimer's Association. All rights reserved.
Conflict of interest statement
With regard to potential conflicts of interest, Marilyn Albert serves as a consultant to Genentech and Eli Lilly and receives grants to her institution from GE Healthcare. Steven DeKosky serves as a consultant to Eisai, Merck, Elan/Wyeth, Novartis, he serves on the advisory board of Pfizer and provides clinical services to United Healthcare. Dennis Dickson report no conflicts. Bruno Dubois serves as a consultant to Affiris, Pierre Fabre, and Eisai, serving on a scientific advisory board for Bristol-Meyers Squibb, Roche, Pfizer, Eli Lilly, and GE Healthcare, and receives grants to his institution from Novartis, Roche, and Eisai. Howard Feldman is an employee of Bristol Meyers Squibb (BMS) and holds stock in BMS; he serves as a consultant to Servier, Glia Scientific, and Pfizer, and serves on a scientific advisory board for Elan, Janssen, Canada, and Wyeth. Nick Fox serves as a consultant (payment to Institute of Neurology) for BMS, Elan/Janssen, Eli Lilly, GE, Lundbeck, and Pfizer/Wyeth. The Institute of Neurology (Nick Fox) has conducted image analysis for Elan/Janssen, Lundbeck, and Pfizer/Wyeth. Anthony Gamst reports no conflicts. David Holtzman serves as a consultant for Bristol-Myers Squibb, Pfizer, and Innogenetics; he serves on a scientific advisory board for En Vivo, Satori, and C2N Diagnostics; and receives grants to his institution from Pfizer, Eli Lilly, and Astra Zeneca. William Jagust serves as a consultant to Genentech, Bayer Healthcare, GE Healthcare. Synarc, Otsuka Pharmaceuticals, Janssen Alzheimer Immunotherapy, Merck, and Tau Rx. Ronald Petersen serves as a consultant for Elan Pharmaceuticals and GE Healthcare and serves on data monitoring committees for Pfizer, Inc., Janssen Alzheimer Immunotherapy. Peter Snyder serves as a consultant to CogState Ltd. Maria Carrillo is an employee of the Alzheimer’s Association and reports no conflicts. Bill Thies is an employee of the Alzheimer’s Association and reports no conflicts. Creighton Phelps is an employee of the U.S. Government and reports no conflicts.
Comment in
-
Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Addressing the challenge of Alzheimer's disease in the 21st century.Alzheimers Dement. 2011 May;7(3):335-7. doi: 10.1016/j.jalz.2011.04.002. Alzheimers Dement. 2011. PMID: 21575876 No abstract available.
Similar articles
-
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21. Alzheimers Dement. 2011. PMID: 21514250 Free PMC article.
-
Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Addressing the challenge of Alzheimer's disease in the 21st century.Alzheimers Dement. 2011 May;7(3):335-7. doi: 10.1016/j.jalz.2011.04.002. Alzheimers Dement. 2011. PMID: 21575876 No abstract available.
-
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.Alzheimers Dement. 2011 May;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. Epub 2011 Apr 21. Alzheimers Dement. 2011. PMID: 21514247 Free PMC article.
-
[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Rev Neurol (Paris). 2012. PMID: 22579080 Review. French.
-
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21. Alzheimers Dement. 2011. PMID: 21514248 Free PMC article.
Cited by
-
FBXL16: a new regulator of neuroinflammation and cognition in Alzheimer's disease through the ubiquitination-dependent degradation of amyloid precursor protein.Biomark Res. 2024 Nov 21;12(1):144. doi: 10.1186/s40364-024-00691-w. Biomark Res. 2024. PMID: 39568047 Free PMC article.
-
Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.J Prev Alzheimers Dis. 2024;11(6):1696-1702. doi: 10.14283/jpad.2024.130. J Prev Alzheimers Dis. 2024. PMID: 39559880 Free PMC article.
-
Intranasal insulin effect on cognitive and/or memory impairment: a systematic review and meta-analysis.Cogn Neurodyn. 2024 Oct;18(5):3059-3073. doi: 10.1007/s11571-024-10138-5. Epub 2024 Jun 13. Cogn Neurodyn. 2024. PMID: 39555259 Review.
-
Association between focal amyloid deposition and cognitive impairment in individuals below the amyloid threshold.Front Aging Neurosci. 2024 Oct 30;16:1452081. doi: 10.3389/fnagi.2024.1452081. eCollection 2024. Front Aging Neurosci. 2024. PMID: 39539457 Free PMC article.
-
Guidelines for the use and interpretation of Alzheimer's disease biomarkers in clinical practice in Brazil: recommendations from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.Dement Neuropsychol. 2024 Nov 11;18:e2024C001. doi: 10.1590/1980-5764-DN-2024-C001. eCollection 2024. Dement Neuropsychol. 2024. PMID: 39534442 Free PMC article.
References
-
- McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. - PMC - PubMed
-
- Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Towards defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:280–92. - PMC - PubMed
-
- Lyketsos C, Colenda C, Beck C, Blank K, Doraiswamy M, Kalunian D, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer’s disease. Am J Geriatr Psychiatry. 2006;14:561–72. - PubMed
-
- Petersen RC, Smith G, Waring S, Ivnik R, Tangalos E, Kokmen E, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
